ZNTL Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.

$76.32  +5.02 (7.04%)
As of 12/07/2021 13:56:21 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/03/2020
Outstanding shares:  45,305,544
Average volume:  258,833
Market cap:   $3,293,713,049
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    98943L107
ISIN:        US98943L1070
Sedol:      BMQ5T49

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   8.19
PS ratio:   0.00
Return on equity:   -37.86%
Net income %:   0.00%